| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver | 110 | 2020 | 492 | 7.880 |
Why?
|
| Hepatitis C, Chronic | 63 | 2015 | 76 | 7.340 |
Why?
|
| Heme | 55 | 2019 | 60 | 5.570 |
Why?
|
| Iron | 40 | 2019 | 94 | 5.130 |
Why?
|
| Hepacivirus | 33 | 2020 | 40 | 4.740 |
Why?
|
| Antiviral Agents | 48 | 2015 | 107 | 4.650 |
Why?
|
| Heme Oxygenase (Decyclizing) | 41 | 2013 | 42 | 4.410 |
Why?
|
| Hepatitis C | 26 | 2020 | 47 | 4.190 |
Why?
|
| Heme Oxygenase-1 | 28 | 2016 | 35 | 4.070 |
Why?
|
| Porphyrias | 27 | 2021 | 27 | 4.060 |
Why?
|
| Porphyria, Acute Intermittent | 14 | 2021 | 16 | 3.590 |
Why?
|
| Interferon-alpha | 46 | 2013 | 68 | 3.520 |
Why?
|
| Porphyria Cutanea Tarda | 13 | 2020 | 15 | 3.400 |
Why?
|
| Liver Cirrhosis | 45 | 2019 | 79 | 3.080 |
Why?
|
| Carcinoma, Hepatocellular | 22 | 2019 | 65 | 2.830 |
Why?
|
| MicroRNAs | 11 | 2018 | 181 | 2.570 |
Why?
|
| Humans | 263 | 2021 | 32274 | 2.540 |
Why?
|
| 5-Aminolevulinate Synthetase | 25 | 2019 | 26 | 2.530 |
Why?
|
| RNA, Messenger | 31 | 2019 | 499 | 2.520 |
Why?
|
| Hepatocytes | 13 | 2018 | 80 | 2.450 |
Why?
|
| Porphyrias, Hepatic | 11 | 2021 | 12 | 2.410 |
Why?
|
| Liver Neoplasms | 23 | 2019 | 164 | 2.320 |
Why?
|
| Liver Transplantation | 13 | 2019 | 185 | 2.280 |
Why?
|
| Polyethylene Glycols | 31 | 2013 | 63 | 2.040 |
Why?
|
| Liver Diseases | 23 | 2017 | 72 | 1.980 |
Why?
|
| Porphyrins | 25 | 2019 | 29 | 1.980 |
Why?
|
| Ribavirin | 26 | 2011 | 28 | 1.910 |
Why?
|
| Gene Expression Regulation, Enzymologic | 14 | 2012 | 83 | 1.870 |
Why?
|
| Protoporphyria, Erythropoietic | 10 | 2020 | 11 | 1.790 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 9 | 2012 | 9 | 1.740 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 9 | 2012 | 10 | 1.740 |
Why?
|
| Male | 152 | 2020 | 19437 | 1.710 |
Why?
|
| Membrane Proteins | 18 | 2016 | 243 | 1.680 |
Why?
|
| Metalloporphyrins | 12 | 2009 | 15 | 1.670 |
Why?
|
| Hepatitis, Autoimmune | 6 | 2015 | 7 | 1.660 |
Why?
|
| Mitochondria | 7 | 2019 | 211 | 1.600 |
Why?
|
| Middle Aged | 119 | 2019 | 11848 | 1.590 |
Why?
|
| Adult | 96 | 2021 | 9256 | 1.570 |
Why?
|
| Female | 132 | 2020 | 19942 | 1.510 |
Why?
|
| Animals | 92 | 2019 | 8199 | 1.430 |
Why?
|
| Mutation | 18 | 2020 | 497 | 1.330 |
Why?
|
| Protoporphyrins | 15 | 2019 | 16 | 1.320 |
Why?
|
| Histocompatibility Antigens Class I | 11 | 2008 | 45 | 1.320 |
Why?
|
| Hemochromatosis | 16 | 2010 | 44 | 1.290 |
Why?
|
| Viral Nonstructural Proteins | 4 | 2011 | 5 | 1.260 |
Why?
|
| Cytokines | 6 | 2018 | 237 | 1.250 |
Why?
|
| Dietary Supplements | 7 | 2019 | 188 | 1.170 |
Why?
|
| Fatty Liver | 10 | 2011 | 70 | 1.110 |
Why?
|
| Coproporphyria, Hereditary | 3 | 2019 | 4 | 1.080 |
Why?
|
| Recombinant Proteins | 43 | 2017 | 264 | 1.070 |
Why?
|
| Chick Embryo | 43 | 2003 | 64 | 1.040 |
Why?
|
| Hepatitis | 4 | 2017 | 9 | 1.030 |
Why?
|
| Polymorphism, Genetic | 9 | 2016 | 179 | 0.990 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2016 | 215 | 0.960 |
Why?
|
| Prognosis | 22 | 2018 | 1534 | 0.950 |
Why?
|
| Porphobilinogen Synthase | 9 | 2019 | 10 | 0.940 |
Why?
|
| Hepatitis B, Chronic | 4 | 2012 | 7 | 0.910 |
Why?
|
| Transfection | 18 | 2017 | 204 | 0.850 |
Why?
|
| Cells, Cultured | 37 | 2017 | 839 | 0.850 |
Why?
|
| Cytochrome P-450 Enzyme System | 20 | 2011 | 26 | 0.840 |
Why?
|
| Aged | 52 | 2019 | 10260 | 0.840 |
Why?
|
| Host-Pathogen Interactions | 3 | 2014 | 24 | 0.830 |
Why?
|
| Acute Disease | 12 | 2017 | 253 | 0.820 |
Why?
|
| RNA, Viral | 17 | 2015 | 49 | 0.790 |
Why?
|
| Drugs, Chinese Herbal | 3 | 2014 | 7 | 0.780 |
Why?
|
| Prospective Studies | 29 | 2019 | 2316 | 0.780 |
Why?
|
| Viral Proteins | 4 | 2013 | 30 | 0.770 |
Why?
|
| Hyperlipidemias | 3 | 2014 | 61 | 0.750 |
Why?
|
| Cell Line, Tumor | 15 | 2017 | 729 | 0.750 |
Why?
|
| Iron Metabolism Disorders | 2 | 2012 | 2 | 0.750 |
Why?
|
| Mitochondrial Proteins | 3 | 2018 | 72 | 0.730 |
Why?
|
| Up-Regulation | 11 | 2017 | 193 | 0.730 |
Why?
|
| Sex Factors | 3 | 2019 | 655 | 0.730 |
Why?
|
| Cholestasis | 7 | 2019 | 18 | 0.710 |
Why?
|
| Porphyria, Variegate | 2 | 2014 | 2 | 0.710 |
Why?
|
| Promoter Regions, Genetic | 12 | 2011 | 203 | 0.710 |
Why?
|
| Phlebotomy | 9 | 2017 | 14 | 0.700 |
Why?
|
| Interferons | 8 | 2015 | 16 | 0.690 |
Why?
|
| Medicine, Chinese Traditional | 2 | 2012 | 3 | 0.680 |
Why?
|
| Oxidative Stress | 11 | 2019 | 255 | 0.680 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2019 | 55 | 0.680 |
Why?
|
| Silymarin | 4 | 2011 | 36 | 0.680 |
Why?
|
| Iron Overload | 6 | 2010 | 24 | 0.670 |
Why?
|
| Hepatitis B | 4 | 2014 | 17 | 0.660 |
Why?
|
| Down-Regulation | 7 | 2014 | 131 | 0.660 |
Why?
|
| Energy Metabolism | 3 | 2019 | 153 | 0.650 |
Why?
|
| Drug Hypersensitivity | 2 | 2017 | 7 | 0.650 |
Why?
|
| Liver Failure, Acute | 2 | 2018 | 10 | 0.640 |
Why?
|
| Pulmonary Embolism | 2 | 2015 | 51 | 0.640 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2013 | 258 | 0.640 |
Why?
|
| HLA Antigens | 7 | 2014 | 40 | 0.640 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 167 | 0.630 |
Why?
|
| Spinal Cord | 2 | 2011 | 137 | 0.630 |
Why?
|
| Pyrroles | 4 | 2013 | 59 | 0.620 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2019 | 4 | 0.620 |
Why?
|
| 3' Untranslated Regions | 3 | 2014 | 25 | 0.610 |
Why?
|
| Biopsy | 22 | 2019 | 252 | 0.610 |
Why?
|
| Porphobilinogen | 7 | 2020 | 9 | 0.610 |
Why?
|
| Central Nervous System | 1 | 2019 | 47 | 0.600 |
Why?
|
| Hepatitis, Viral, Human | 3 | 2015 | 6 | 0.600 |
Why?
|
| Brain | 5 | 2019 | 965 | 0.590 |
Why?
|
| Mesenteric Arteries | 1 | 2019 | 20 | 0.580 |
Why?
|
| United States | 20 | 2021 | 4072 | 0.570 |
Why?
|
| Genotype | 18 | 2017 | 702 | 0.570 |
Why?
|
| Alanine Transaminase | 18 | 2016 | 47 | 0.570 |
Why?
|
| Oxygen | 1 | 2019 | 138 | 0.560 |
Why?
|
| Antioxidants | 4 | 2011 | 122 | 0.560 |
Why?
|
| Rats | 28 | 2014 | 1895 | 0.560 |
Why?
|
| Diagnosis, Differential | 10 | 2017 | 502 | 0.550 |
Why?
|
| Quality of Life | 7 | 2019 | 964 | 0.550 |
Why?
|
| Heptanoic Acids | 2 | 2009 | 33 | 0.550 |
Why?
|
| Reactive Oxygen Species | 4 | 2011 | 163 | 0.550 |
Why?
|
| Hepatitis B virus | 3 | 2014 | 5 | 0.540 |
Why?
|
| Immunologic Tests | 1 | 2017 | 4 | 0.540 |
Why?
|
| Autoantibodies | 3 | 2014 | 50 | 0.540 |
Why?
|
| Isoniazid | 1 | 2017 | 4 | 0.540 |
Why?
|
| Biopsy, Needle | 7 | 2017 | 94 | 0.540 |
Why?
|
| Bile Ducts | 3 | 2017 | 19 | 0.540 |
Why?
|
| Virus Internalization | 2 | 2014 | 7 | 0.530 |
Why?
|
| Treatment Outcome | 23 | 2019 | 3416 | 0.530 |
Why?
|
| Lymphocyte Activation | 2 | 2017 | 94 | 0.530 |
Why?
|
| Disease Progression | 20 | 2019 | 591 | 0.520 |
Why?
|
| Risk Factors | 23 | 2019 | 3934 | 0.520 |
Why?
|
| Adolescent | 14 | 2021 | 3517 | 0.520 |
Why?
|
| Time Factors | 21 | 2016 | 2204 | 0.520 |
Why?
|
| Bile Duct Diseases | 1 | 2017 | 10 | 0.510 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2018 | 51 | 0.510 |
Why?
|
| Enzyme Induction | 21 | 2007 | 31 | 0.500 |
Why?
|
| Autoimmunity | 2 | 2014 | 31 | 0.490 |
Why?
|
| Patient Selection | 3 | 2014 | 272 | 0.490 |
Why?
|
| Glutethimide | 12 | 2005 | 12 | 0.490 |
Why?
|
| Tea | 2 | 2006 | 2 | 0.480 |
Why?
|
| Camellia sinensis | 2 | 2006 | 2 | 0.480 |
Why?
|
| Deferoxamine | 8 | 2009 | 8 | 0.480 |
Why?
|
| Liver Failure | 3 | 2014 | 21 | 0.480 |
Why?
|
| Hepatitis E | 2 | 2013 | 6 | 0.480 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2015 | 4 | 0.460 |
Why?
|
| Genetic Testing | 2 | 2013 | 90 | 0.460 |
Why?
|
| Chronic Disease | 16 | 2013 | 413 | 0.460 |
Why?
|
| Child | 8 | 2021 | 2434 | 0.460 |
Why?
|
| Ferrochelatase | 5 | 2020 | 5 | 0.460 |
Why?
|
| Severity of Illness Index | 13 | 2019 | 853 | 0.450 |
Why?
|
| Aged, 80 and over | 15 | 2019 | 3898 | 0.450 |
Why?
|
| Virus Activation | 1 | 2014 | 8 | 0.440 |
Why?
|
| Hemin | 5 | 2017 | 5 | 0.430 |
Why?
|
| RNA, Small Interfering | 7 | 2019 | 112 | 0.430 |
Why?
|
| Thiazoles | 4 | 2013 | 36 | 0.430 |
Why?
|
| Viral Core Proteins | 2 | 2011 | 2 | 0.430 |
Why?
|
| Cell Respiration | 3 | 2011 | 20 | 0.430 |
Why?
|
| Gastroenterology | 1 | 2014 | 3 | 0.430 |
Why?
|
| Mitochondria, Liver | 3 | 2011 | 6 | 0.430 |
Why?
|
| Gene Expression Profiling | 4 | 2013 | 314 | 0.430 |
Why?
|
| Plant Preparations | 4 | 2015 | 27 | 0.420 |
Why?
|
| Bilirubin | 9 | 2016 | 23 | 0.420 |
Why?
|
| Rats, Sprague-Dawley | 10 | 2014 | 897 | 0.410 |
Why?
|
| Tandem Mass Spectrometry | 4 | 2013 | 40 | 0.410 |
Why?
|
| NF-E2-Related Factor 2 | 3 | 2011 | 12 | 0.410 |
Why?
|
| RNA, Untranslated | 1 | 2013 | 10 | 0.410 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 395 | 0.410 |
Why?
|
| Hypertension, Portal | 3 | 2010 | 10 | 0.410 |
Why?
|
| Mixed Function Oxygenases | 7 | 1992 | 12 | 0.400 |
Why?
|
| Gene Expression Regulation | 8 | 2019 | 478 | 0.390 |
Why?
|
| Stress, Psychological | 1 | 2015 | 217 | 0.390 |
Why?
|
| Chromatography, Liquid | 3 | 2012 | 33 | 0.390 |
Why?
|
| Young Adult | 10 | 2019 | 2648 | 0.390 |
Why?
|
| Proteomics | 5 | 2012 | 97 | 0.390 |
Why?
|
| Transcription, Genetic | 5 | 2011 | 140 | 0.390 |
Why?
|
| Circadian Rhythm | 1 | 2013 | 46 | 0.390 |
Why?
|
| Ferritins | 5 | 2015 | 38 | 0.390 |
Why?
|
| Cytoskeletal Proteins | 1 | 2013 | 16 | 0.380 |
Why?
|
| Chickens | 11 | 2005 | 36 | 0.380 |
Why?
|
| Heptanoates | 7 | 2013 | 7 | 0.370 |
Why?
|
| Porphyria, Hepatoerythropoietic | 3 | 2002 | 3 | 0.370 |
Why?
|
| Vimentin | 2 | 2012 | 10 | 0.370 |
Why?
|
| Acetylgalactosamine | 3 | 2021 | 3 | 0.370 |
Why?
|
| Superoxide Dismutase | 2 | 2011 | 41 | 0.370 |
Why?
|
| Phenobarbital | 7 | 2019 | 7 | 0.370 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 1223 | 0.370 |
Why?
|
| Pyrrolidines | 3 | 2021 | 16 | 0.370 |
Why?
|
| Proteome | 4 | 2013 | 41 | 0.360 |
Why?
|
| Case-Control Studies | 6 | 2018 | 854 | 0.350 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2019 | 821 | 0.350 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2011 | 14 | 0.350 |
Why?
|
| Signal Transduction | 6 | 2019 | 727 | 0.350 |
Why?
|
| Contractile Proteins | 1 | 2011 | 6 | 0.350 |
Why?
|
| Cell Line | 9 | 2014 | 454 | 0.350 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2019 | 717 | 0.350 |
Why?
|
| Serum Albumin, Bovine | 2 | 2010 | 11 | 0.340 |
Why?
|
| Peptide Hydrolases | 1 | 2011 | 17 | 0.340 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 2009 | 11 | 0.340 |
Why?
|
| Brain Chemistry | 1 | 2011 | 46 | 0.340 |
Why?
|
| Microfilament Proteins | 1 | 2011 | 37 | 0.340 |
Why?
|
| Ethanol | 4 | 2011 | 195 | 0.340 |
Why?
|
| Thiazolidinediones | 2 | 2002 | 46 | 0.330 |
Why?
|
| Blotting, Western | 7 | 2012 | 299 | 0.330 |
Why?
|
| Arsenicals | 2 | 2001 | 12 | 0.330 |
Why?
|
| Plasmapheresis | 2 | 2002 | 11 | 0.330 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 141 | 0.330 |
Why?
|
| Albumins | 2 | 2002 | 42 | 0.330 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2009 | 78 | 0.330 |
Why?
|
| Indoles | 2 | 2013 | 65 | 0.330 |
Why?
|
| Incidence | 9 | 2017 | 1241 | 0.320 |
Why?
|
| Phytotherapy | 1 | 2010 | 36 | 0.310 |
Why?
|
| Microsomes, Liver | 7 | 1995 | 11 | 0.310 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2009 | 9 | 0.310 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2009 | 23 | 0.310 |
Why?
|
| Hypoglycemic Agents | 2 | 2002 | 186 | 0.310 |
Why?
|
| Cryoglobulinemia | 4 | 2001 | 6 | 0.300 |
Why?
|
| Parenteral Nutrition | 4 | 1994 | 13 | 0.300 |
Why?
|
| Interleukins | 3 | 2015 | 17 | 0.300 |
Why?
|
| Viral Load | 8 | 2013 | 73 | 0.300 |
Why?
|
| Registries | 5 | 2018 | 294 | 0.300 |
Why?
|
| Postoperative Complications | 2 | 2008 | 823 | 0.300 |
Why?
|
| Calcium | 4 | 2019 | 339 | 0.290 |
Why?
|
| Drug Therapy, Combination | 14 | 2011 | 292 | 0.290 |
Why?
|
| Sequence Deletion | 3 | 2011 | 38 | 0.290 |
Why?
|
| Base Sequence | 7 | 2010 | 252 | 0.290 |
Why?
|
| Methadone | 1 | 2008 | 12 | 0.280 |
Why?
|
| Genes, Reporter | 4 | 2004 | 41 | 0.280 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2008 | 7 | 0.280 |
Why?
|
| Uroporphyrins | 8 | 2019 | 8 | 0.280 |
Why?
|
| Narcotics | 1 | 2008 | 32 | 0.280 |
Why?
|
| Mice | 8 | 2019 | 2571 | 0.280 |
Why?
|
| Disease Models, Animal | 7 | 2019 | 1083 | 0.280 |
Why?
|
| Aminolevulinic Acid | 5 | 2020 | 8 | 0.280 |
Why?
|
| Alkaline Phosphatase | 7 | 2016 | 40 | 0.280 |
Why?
|
| Sural Nerve | 1 | 2008 | 25 | 0.280 |
Why?
|
| Phenotype | 8 | 2021 | 621 | 0.280 |
Why?
|
| Gastric Bypass | 1 | 2008 | 29 | 0.270 |
Why?
|
| Biomedical Research | 1 | 2010 | 178 | 0.270 |
Why?
|
| Serum Albumin | 5 | 2016 | 56 | 0.270 |
Why?
|
| Molecular Sequence Data | 10 | 2011 | 359 | 0.270 |
Why?
|
| Urine | 1 | 2008 | 69 | 0.270 |
Why?
|
| Risk Assessment | 6 | 2017 | 1425 | 0.270 |
Why?
|
| Recurrence | 7 | 2019 | 285 | 0.260 |
Why?
|
| Chemokine CCL2 | 2 | 2018 | 48 | 0.260 |
Why?
|
| Bone Morphogenetic Protein 4 | 2 | 2017 | 13 | 0.260 |
Why?
|
| Anxiety | 3 | 2019 | 190 | 0.260 |
Why?
|
| Cohort Studies | 7 | 2017 | 1840 | 0.260 |
Why?
|
| Hyperbilirubinemia | 1 | 2007 | 2 | 0.260 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2007 | 3 | 0.260 |
Why?
|
| Follow-Up Studies | 13 | 2017 | 2240 | 0.260 |
Why?
|
| Microsatellite Repeats | 1 | 2007 | 22 | 0.260 |
Why?
|
| Nitrilotriacetic Acid | 6 | 2009 | 7 | 0.250 |
Why?
|
| Pancreatic Neoplasms | 3 | 2013 | 131 | 0.250 |
Why?
|
| T-Lymphocytes | 5 | 2011 | 140 | 0.250 |
Why?
|
| Ferric Compounds | 6 | 2009 | 15 | 0.250 |
Why?
|
| Sunlight | 2 | 2017 | 17 | 0.250 |
Why?
|
| Simvastatin | 1 | 2006 | 26 | 0.250 |
Why?
|
| Neuralgia | 2 | 2019 | 46 | 0.240 |
Why?
|
| Virus Replication | 3 | 2013 | 42 | 0.240 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 792 | 0.230 |
Why?
|
| Pilot Projects | 3 | 2019 | 553 | 0.230 |
Why?
|
| Genetic Diseases, X-Linked | 2 | 2017 | 9 | 0.230 |
Why?
|
| Alcohol Drinking | 1 | 2008 | 255 | 0.230 |
Why?
|
| Antidepressive Agents | 2 | 2010 | 74 | 0.230 |
Why?
|
| Genetic Variation | 4 | 2012 | 248 | 0.230 |
Why?
|
| Diet, Reducing | 1 | 2006 | 85 | 0.230 |
Why?
|
| Antibodies, Monoclonal | 5 | 2014 | 245 | 0.220 |
Why?
|
| Bile | 1 | 2005 | 7 | 0.220 |
Why?
|
| Embolism, Air | 1 | 2005 | 5 | 0.220 |
Why?
|
| Adenosine Triphosphate | 2 | 2019 | 71 | 0.220 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2005 | 29 | 0.220 |
Why?
|
| Hepatitis, Chronic | 2 | 2011 | 2 | 0.220 |
Why?
|
| Hepatitis, Alcoholic | 3 | 2000 | 6 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2012 | 541 | 0.210 |
Why?
|
| Sodium Compounds | 3 | 2000 | 3 | 0.210 |
Why?
|
| Arsenites | 3 | 2000 | 4 | 0.210 |
Why?
|
| Interferon Type I | 2 | 2007 | 11 | 0.210 |
Why?
|
| Antihypertensive Agents | 2 | 2014 | 363 | 0.210 |
Why?
|
| Gene Expression | 5 | 2008 | 345 | 0.210 |
Why?
|
| Chromans | 2 | 2002 | 6 | 0.200 |
Why?
|
| Erythrocytes | 3 | 2015 | 41 | 0.200 |
Why?
|
| Prevalence | 8 | 2021 | 955 | 0.200 |
Why?
|
| Immunohistochemistry | 4 | 2017 | 543 | 0.200 |
Why?
|
| Allantois | 1 | 2003 | 3 | 0.200 |
Why?
|
| Hepatic Stellate Cells | 2 | 2014 | 4 | 0.200 |
Why?
|
| Transcription Factors | 1 | 2004 | 183 | 0.200 |
Why?
|
| Chorion | 1 | 2003 | 9 | 0.200 |
Why?
|
| Retrospective Studies | 7 | 2017 | 3624 | 0.200 |
Why?
|
| Sensitivity and Specificity | 5 | 2016 | 556 | 0.200 |
Why?
|
| Heterozygote | 3 | 2002 | 60 | 0.200 |
Why?
|
| Probucol | 1 | 2003 | 1 | 0.200 |
Why?
|
| Kupffer Cells | 4 | 2018 | 10 | 0.190 |
Why?
|
| Receptors, Transferrin | 1 | 2002 | 10 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 246 | 0.190 |
Why?
|
| Catechin | 2 | 2013 | 4 | 0.190 |
Why?
|
| Drug Administration Schedule | 5 | 2019 | 276 | 0.190 |
Why?
|
| Transferrin | 7 | 2010 | 26 | 0.190 |
Why?
|
| Nutritional Physiological Phenomena | 2 | 1994 | 16 | 0.190 |
Why?
|
| Hep G2 Cells | 4 | 2019 | 24 | 0.190 |
Why?
|
| Cation Transport Proteins | 2 | 2018 | 22 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2003 | 113 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 324 | 0.190 |
Why?
|
| Immunologic Factors | 2 | 2013 | 53 | 0.190 |
Why?
|
| Liver Function Tests | 4 | 2014 | 22 | 0.180 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 2 | 2000 | 2 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 2 | 2017 | 38 | 0.180 |
Why?
|
| Protein Binding | 3 | 2011 | 244 | 0.180 |
Why?
|
| Enzyme Inhibitors | 5 | 2001 | 174 | 0.180 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 595 | 0.180 |
Why?
|
| Half-Life | 4 | 2009 | 24 | 0.180 |
Why?
|
| Oxandrolone | 2 | 1991 | 2 | 0.180 |
Why?
|
| Pain | 3 | 2020 | 303 | 0.180 |
Why?
|
| Antigens, CD | 5 | 2015 | 97 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 1999 | 41 | 0.170 |
Why?
|
| Splanchnic Circulation | 1 | 2001 | 3 | 0.170 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 160 | 0.170 |
Why?
|
| Lymphocytes | 2 | 2018 | 55 | 0.170 |
Why?
|
| Hemopexin | 3 | 1996 | 3 | 0.170 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 2 | 1991 | 9 | 0.170 |
Why?
|
| Ubiquitins | 1 | 2000 | 2 | 0.170 |
Why?
|
| beta-Thalassemia | 1 | 2000 | 11 | 0.170 |
Why?
|
| Binding Sites | 3 | 2014 | 144 | 0.170 |
Why?
|
| Necrosis | 2 | 2018 | 54 | 0.160 |
Why?
|
| Dactinomycin | 4 | 2008 | 13 | 0.160 |
Why?
|
| Genes, MHC Class I | 2 | 1999 | 5 | 0.160 |
Why?
|
| Platelet Count | 4 | 2009 | 23 | 0.160 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2000 | 24 | 0.160 |
Why?
|
| Computational Biology | 2 | 2011 | 99 | 0.160 |
Why?
|
| Cell Proliferation | 3 | 2017 | 603 | 0.160 |
Why?
|
| Oxidation-Reduction | 5 | 2019 | 274 | 0.160 |
Why?
|
| Iron Chelating Agents | 3 | 2010 | 6 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 3 | 2014 | 191 | 0.160 |
Why?
|
| DNA | 4 | 2004 | 223 | 0.160 |
Why?
|
| Anti-Anxiety Agents | 1 | 1999 | 12 | 0.160 |
Why?
|
| Iron, Dietary | 1 | 2019 | 8 | 0.150 |
Why?
|
| Tumor Cells, Cultured | 6 | 2010 | 164 | 0.150 |
Why?
|
| Uroporphyrinogen Decarboxylase | 4 | 2007 | 4 | 0.150 |
Why?
|
| Predictive Value of Tests | 5 | 2013 | 883 | 0.150 |
Why?
|
| Kinetics | 7 | 1998 | 250 | 0.150 |
Why?
|
| Sex Distribution | 3 | 2016 | 174 | 0.150 |
Why?
|
| Electron Transport | 1 | 2019 | 16 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 4 | 2006 | 186 | 0.150 |
Why?
|
| Glutamic Acid | 2 | 2010 | 50 | 0.150 |
Why?
|
| Virulence | 1 | 2019 | 20 | 0.150 |
Why?
|
| Magnetic Field Therapy | 1 | 2019 | 15 | 0.150 |
Why?
|
| Statistics, Nonparametric | 2 | 2017 | 128 | 0.150 |
Why?
|
| Liver Diseases, Alcoholic | 3 | 2011 | 6 | 0.150 |
Why?
|
| Databases, Factual | 2 | 2019 | 368 | 0.150 |
Why?
|
| Intestinal Mucosa | 2 | 2002 | 73 | 0.150 |
Why?
|
| Hydroxymethylbilane Synthase | 1 | 2019 | 1 | 0.150 |
Why?
|
| Calcium Channels, T-Type | 1 | 2019 | 28 | 0.150 |
Why?
|
| Leupeptins | 2 | 2009 | 7 | 0.150 |
Why?
|
| Blood Platelets | 1 | 2019 | 59 | 0.150 |
Why?
|
| Age Factors | 3 | 2017 | 1179 | 0.150 |
Why?
|
| Amides | 1 | 2019 | 24 | 0.150 |
Why?
|
| Phenylephrine | 1 | 2019 | 34 | 0.150 |
Why?
|
| Oligopeptides | 2 | 2009 | 49 | 0.140 |
Why?
|
| Drug Synergism | 5 | 2013 | 66 | 0.140 |
Why?
|
| Aspartate Aminotransferases | 7 | 2011 | 29 | 0.140 |
Why?
|
| Muscles | 1 | 2019 | 69 | 0.140 |
Why?
|
| Infant | 2 | 2019 | 1010 | 0.140 |
Why?
|
| RNA Interference | 3 | 2008 | 78 | 0.140 |
Why?
|
| Acetylcholine | 1 | 2019 | 69 | 0.140 |
Why?
|
| Analgesics | 1 | 1999 | 111 | 0.140 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2019 | 54 | 0.140 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2009 | 37 | 0.140 |
Why?
|
| Models, Animal | 2 | 2011 | 188 | 0.140 |
Why?
|
| Vasodilation | 1 | 2019 | 92 | 0.140 |
Why?
|
| Antigens, Viral | 3 | 2011 | 21 | 0.140 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 287 | 0.140 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 6 | 0.140 |
Why?
|
| Colon | 2 | 1999 | 72 | 0.140 |
Why?
|
| Ceruloplasmin | 1 | 2018 | 5 | 0.140 |
Why?
|
| Genes | 1 | 2018 | 13 | 0.140 |
Why?
|
| Intestines | 2 | 1999 | 63 | 0.140 |
Why?
|
| Granzymes | 1 | 2017 | 7 | 0.140 |
Why?
|
| alpha-Fetoproteins | 2 | 2009 | 10 | 0.140 |
Why?
|
| Secondary Prevention | 2 | 2013 | 73 | 0.140 |
Why?
|
| Adaptive Immunity | 1 | 2017 | 16 | 0.130 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2004 | 63 | 0.130 |
Why?
|
| Insulin | 2 | 2018 | 359 | 0.130 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 41 | 0.130 |
Why?
|
| Haptoglobins | 2 | 2015 | 5 | 0.130 |
Why?
|
| Analysis of Variance | 3 | 2013 | 471 | 0.130 |
Why?
|
| Organoids | 1 | 2018 | 99 | 0.130 |
Why?
|
| Sexual Behavior | 2 | 2010 | 130 | 0.130 |
Why?
|
| Multiple Chemical Sensitivity | 1 | 1997 | 1 | 0.130 |
Why?
|
| Depression | 3 | 2019 | 420 | 0.130 |
Why?
|
| Inhibitor of Differentiation Protein 2 | 1 | 2017 | 5 | 0.130 |
Why?
|
| Hemolysis | 2 | 2015 | 11 | 0.130 |
Why?
|
| Feasibility Studies | 1 | 2017 | 308 | 0.120 |
Why?
|
| Sterol Esterase | 1 | 2016 | 1 | 0.120 |
Why?
|
| International Cooperation | 1 | 1996 | 31 | 0.120 |
Why?
|
| Metabolic Diseases | 1 | 1996 | 17 | 0.120 |
Why?
|
| Apoptosis | 3 | 2013 | 375 | 0.120 |
Why?
|
| Cholangitis | 1 | 1996 | 4 | 0.120 |
Why?
|
| Transforming Growth Factor beta | 2 | 2012 | 63 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 1996 | 42 | 0.120 |
Why?
|
| Lipase | 1 | 2016 | 30 | 0.120 |
Why?
|
| Organometallic Compounds | 2 | 1994 | 18 | 0.120 |
Why?
|
| Glutathione | 3 | 2001 | 54 | 0.120 |
Why?
|
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2016 | 2 | 0.120 |
Why?
|
| Jaundice, Obstructive | 1 | 2016 | 2 | 0.120 |
Why?
|
| Models, Biological | 4 | 2013 | 408 | 0.120 |
Why?
|
| Enhancer Elements, Genetic | 3 | 2002 | 19 | 0.120 |
Why?
|
| Ferrous Compounds | 2 | 1994 | 6 | 0.120 |
Why?
|
| China | 2 | 2021 | 56 | 0.120 |
Why?
|
| Metallothionein | 1 | 1996 | 3 | 0.120 |
Why?
|
| Neurons | 2 | 2011 | 486 | 0.120 |
Why?
|
| Menopause | 1 | 2017 | 109 | 0.120 |
Why?
|
| Immunoglobulin G | 3 | 2013 | 129 | 0.120 |
Why?
|
| Lead Poisoning | 1 | 2015 | 2 | 0.120 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2015 | 7 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2020 | 293 | 0.120 |
Why?
|
| Fibrinolysis | 1 | 2015 | 13 | 0.120 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 1995 | 2 | 0.120 |
Why?
|
| alpha-MSH | 1 | 2015 | 2 | 0.120 |
Why?
|
| Amino Acid Sequence | 6 | 2011 | 290 | 0.120 |
Why?
|
| Erythropoietin | 1 | 2015 | 31 | 0.110 |
Why?
|
| Skin Diseases | 2 | 1989 | 135 | 0.110 |
Why?
|
| Isoenzymes | 3 | 1999 | 67 | 0.110 |
Why?
|
| Portal System | 2 | 2011 | 13 | 0.110 |
Why?
|
| Kidney | 3 | 1995 | 521 | 0.110 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 39 | 0.110 |
Why?
|
| Double-Blind Method | 4 | 2020 | 565 | 0.110 |
Why?
|
| Killer Cells, Natural | 1 | 2015 | 21 | 0.110 |
Why?
|
| Fatigue | 4 | 2020 | 76 | 0.110 |
Why?
|
| Longitudinal Studies | 5 | 2019 | 757 | 0.110 |
Why?
|
| Rats, Inbred Strains | 8 | 1992 | 76 | 0.110 |
Why?
|
| DNA Primers | 2 | 2008 | 84 | 0.110 |
Why?
|
| Homeostasis | 1 | 2015 | 130 | 0.110 |
Why?
|
| Anthracyclines | 1 | 2015 | 52 | 0.110 |
Why?
|
| Inflammation | 1 | 2018 | 506 | 0.110 |
Why?
|
| Mifepristone | 1 | 1994 | 4 | 0.110 |
Why?
|
| Claudins | 1 | 2014 | 8 | 0.110 |
Why?
|
| Immunoglobulins | 1 | 2014 | 13 | 0.110 |
Why?
|
| Hepatitis B Vaccines | 1 | 2014 | 10 | 0.110 |
Why?
|
| Autoimmune Diseases | 3 | 2013 | 46 | 0.110 |
Why?
|
| Tangier Disease | 1 | 1994 | 5 | 0.110 |
Why?
|
| Databases, Genetic | 1 | 2014 | 39 | 0.110 |
Why?
|
| Transcription Factor AP-1 | 3 | 1999 | 19 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2015 | 79 | 0.110 |
Why?
|
| Hypergammaglobulinemia | 1 | 2014 | 1 | 0.110 |
Why?
|
| Methyldopa | 1 | 2014 | 1 | 0.110 |
Why?
|
| Drug Costs | 1 | 2014 | 46 | 0.110 |
Why?
|
| Nitrofurantoin | 1 | 2014 | 2 | 0.110 |
Why?
|
| Lectins | 2 | 2011 | 11 | 0.110 |
Why?
|
| Hydralazine | 1 | 2014 | 6 | 0.110 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2014 | 3 | 0.110 |
Why?
|
| Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2014 | 1 | 0.110 |
Why?
|
| Adipokines | 2 | 2011 | 11 | 0.110 |
Why?
|
| Minocycline | 1 | 2014 | 11 | 0.110 |
Why?
|
| Cell Transdifferentiation | 1 | 2014 | 7 | 0.110 |
Why?
|
| Delayed Diagnosis | 1 | 2014 | 18 | 0.110 |
Why?
|
| Thrombocytopenia | 3 | 2010 | 30 | 0.110 |
Why?
|
| Intestinal Polyps | 1 | 1994 | 3 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 99 | 0.100 |
Why?
|
| Luciferases | 3 | 2000 | 33 | 0.100 |
Why?
|
| Ascites | 3 | 2009 | 13 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 150 | 0.100 |
Why?
|
| Response Elements | 3 | 2004 | 16 | 0.100 |
Why?
|
| Nutrition Disorders | 2 | 1994 | 10 | 0.100 |
Why?
|
| Protein-Energy Malnutrition | 1 | 1994 | 4 | 0.100 |
Why?
|
| Cobalt | 3 | 2000 | 4 | 0.100 |
Why?
|
| Acetaminophen | 1 | 1994 | 19 | 0.100 |
Why?
|
| Models, Immunological | 1 | 2013 | 8 | 0.100 |
Why?
|
| Rectal Neoplasms | 1 | 1994 | 19 | 0.100 |
Why?
|
| Allylisopropylacetamide | 4 | 1996 | 4 | 0.100 |
Why?
|
| Lung Diseases | 1 | 1994 | 50 | 0.100 |
Why?
|
| Renal Insufficiency | 1 | 1994 | 57 | 0.100 |
Why?
|
| Enteral Nutrition | 1 | 1994 | 29 | 0.100 |
Why?
|
| Hydrogen Peroxide | 2 | 2011 | 85 | 0.100 |
Why?
|
| Proteins | 4 | 2012 | 149 | 0.100 |
Why?
|
| Thiocyanates | 1 | 1993 | 3 | 0.100 |
Why?
|
| Guanidines | 1 | 1993 | 7 | 0.100 |
Why?
|
| Pyruvic Acid | 2 | 2010 | 6 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2014 | 251 | 0.100 |
Why?
|
| Isothiocyanates | 1 | 1993 | 14 | 0.100 |
Why?
|
| Collagen | 3 | 2009 | 229 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2013 | 90 | 0.100 |
Why?
|
| Melatonin | 1 | 2013 | 8 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2013 | 82 | 0.100 |
Why?
|
| Gene Deletion | 2 | 2004 | 66 | 0.100 |
Why?
|
| Epilepsy | 1 | 2014 | 79 | 0.100 |
Why?
|
| Injections, Subcutaneous | 3 | 2020 | 36 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2007 | 555 | 0.100 |
Why?
|
| Biological Transport, Active | 1 | 2013 | 7 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2013 | 11 | 0.100 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2010 | 4 | 0.100 |
Why?
|
| Interferon-beta | 1 | 2013 | 19 | 0.100 |
Why?
|
| Hydrocortisone | 1 | 2013 | 61 | 0.100 |
Why?
|
| Cell Nucleus | 1 | 1993 | 111 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 100 | 0.090 |
Why?
|
| Camphor | 1 | 1992 | 1 | 0.090 |
Why?
|
| Famous Persons | 1 | 1992 | 1 | 0.090 |
Why?
|
| Monoterpenes | 1 | 1992 | 3 | 0.090 |
Why?
|
| tert-Butylhydroperoxide | 1 | 2012 | 4 | 0.090 |
Why?
|
| Terpenes | 1 | 1992 | 6 | 0.090 |
Why?
|
| Antimalarials | 1 | 2012 | 8 | 0.090 |
Why?
|
| Biliverdine | 2 | 1989 | 2 | 0.090 |
Why?
|
| World Health Organization | 1 | 2012 | 17 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2011 | 95 | 0.090 |
Why?
|
| Nuclear Proteins | 2 | 2004 | 74 | 0.090 |
Why?
|
| Stroke Volume | 1 | 2015 | 417 | 0.090 |
Why?
|
| Hepatitis E virus | 1 | 2011 | 3 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2009 | 651 | 0.090 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 62 | 0.090 |
Why?
|
| Serum | 1 | 2011 | 14 | 0.090 |
Why?
|
| Androgens | 1 | 2011 | 30 | 0.090 |
Why?
|
| Cell Extracts | 1 | 2011 | 2 | 0.090 |
Why?
|
| Cycloheximide | 2 | 2008 | 10 | 0.090 |
Why?
|
| Nitrogen | 1 | 1991 | 10 | 0.090 |
Why?
|
| Feces | 1 | 2011 | 41 | 0.090 |
Why?
|
| Limit of Detection | 1 | 2011 | 12 | 0.090 |
Why?
|
| Inclusion Bodies | 1 | 2011 | 2 | 0.090 |
Why?
|
| Calibration | 1 | 2011 | 24 | 0.090 |
Why?
|
| Osteoarthritis | 1 | 2012 | 73 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2012 | 1050 | 0.090 |
Why?
|
| Protein Synthesis Inhibitors | 2 | 2008 | 11 | 0.090 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 146 | 0.090 |
Why?
|
| Porins | 1 | 2011 | 1 | 0.090 |
Why?
|
| Diabetes Mellitus | 2 | 2007 | 390 | 0.090 |
Why?
|
| Telomere | 1 | 2011 | 11 | 0.090 |
Why?
|
| Antibodies | 1 | 1991 | 56 | 0.090 |
Why?
|
| RNA Stability | 1 | 2011 | 4 | 0.090 |
Why?
|
| Transaminases | 2 | 2020 | 10 | 0.090 |
Why?
|
| Demyelinating Diseases | 1 | 2011 | 9 | 0.090 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 33 | 0.090 |
Why?
|
| Aflatoxins | 1 | 1991 | 1 | 0.090 |
Why?
|
| Rats, Transgenic | 1 | 2011 | 47 | 0.090 |
Why?
|
| Leukopenia | 2 | 2008 | 9 | 0.090 |
Why?
|
| Cell Death | 1 | 2011 | 79 | 0.090 |
Why?
|
| Mitochondrial Membranes | 1 | 2011 | 27 | 0.090 |
Why?
|
| Hemeproteins | 1 | 2011 | 1 | 0.090 |
Why?
|
| Protein Transport | 1 | 2011 | 80 | 0.090 |
Why?
|
| Carcinogens | 1 | 1991 | 36 | 0.090 |
Why?
|
| Pyruvates | 1 | 2011 | 2 | 0.080 |
Why?
|
| Malates | 1 | 2011 | 2 | 0.080 |
Why?
|
| Protein Engineering | 1 | 2011 | 19 | 0.080 |
Why?
|
| Glutamates | 1 | 2011 | 10 | 0.080 |
Why?
|
| Motor Neurons | 1 | 2011 | 50 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2011 | 68 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2011 | 200 | 0.080 |
Why?
|
| Stomach Diseases | 1 | 2010 | 7 | 0.080 |
Why?
|
| Benzoates | 1 | 2010 | 7 | 0.080 |
Why?
|
| Hemosiderosis | 1 | 1990 | 1 | 0.080 |
Why?
|
| Triazoles | 1 | 2010 | 15 | 0.080 |
Why?
|
| Ketoglutaric Acids | 1 | 2010 | 5 | 0.080 |
Why?
|
| Succinic Acid | 1 | 2010 | 2 | 0.080 |
Why?
|
| Injections, Intravenous | 2 | 2002 | 99 | 0.080 |
Why?
|
| Estrogens | 1 | 2011 | 194 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2006 | 97 | 0.080 |
Why?
|
| Thiophenes | 1 | 2010 | 24 | 0.080 |
Why?
|
| Bone Diseases, Metabolic | 1 | 1990 | 20 | 0.080 |
Why?
|
| Gene Regulatory Networks | 1 | 2010 | 45 | 0.080 |
Why?
|
| Cluster Analysis | 1 | 2010 | 120 | 0.080 |
Why?
|
| Alcoholism | 2 | 1994 | 97 | 0.080 |
Why?
|
| Health Surveys | 2 | 2009 | 175 | 0.080 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2010 | 22 | 0.080 |
Why?
|
| Choline Deficiency | 1 | 1989 | 1 | 0.080 |
Why?
|
| Phenylurea Compounds | 1 | 2009 | 10 | 0.080 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2009 | 6 | 0.080 |
Why?
|
| Zebrafish | 2 | 2019 | 23 | 0.080 |
Why?
|
| Carbamates | 1 | 2009 | 16 | 0.080 |
Why?
|
| Coffee | 1 | 2009 | 8 | 0.080 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2001 | 7 | 0.080 |
Why?
|
| Protein Stability | 1 | 2009 | 27 | 0.080 |
Why?
|
| Choline | 1 | 1989 | 18 | 0.080 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2009 | 1 | 0.080 |
Why?
|
| Hepatitis B e Antigens | 1 | 2009 | 1 | 0.080 |
Why?
|
| Ubiquitination | 1 | 2009 | 15 | 0.080 |
Why?
|
| Protein Precursors | 1 | 2009 | 24 | 0.080 |
Why?
|
| Acetates | 1 | 1989 | 14 | 0.080 |
Why?
|
| Antipyrine | 2 | 1991 | 2 | 0.080 |
Why?
|
| Depressive Disorder | 1 | 2010 | 69 | 0.080 |
Why?
|
| Sulfhydryl Compounds | 2 | 2001 | 35 | 0.080 |
Why?
|
| Atenolol | 1 | 1989 | 5 | 0.080 |
Why?
|
| Restriction Mapping | 2 | 2004 | 14 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2010 | 95 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1989 | 20 | 0.070 |
Why?
|
| Levulinic Acids | 2 | 1987 | 2 | 0.070 |
Why?
|
| Continental Population Groups | 1 | 2010 | 228 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2000 | 120 | 0.070 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2008 | 3 | 0.070 |
Why?
|
| Carboxy-Lyases | 2 | 1985 | 4 | 0.070 |
Why?
|
| Directly Observed Therapy | 1 | 2008 | 1 | 0.070 |
Why?
|
| Tetrazolium Salts | 1 | 2008 | 5 | 0.070 |
Why?
|
| Tryptophan Oxygenase | 1 | 1988 | 1 | 0.070 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 2 | 2000 | 3 | 0.070 |
Why?
|
| Quadriplegia | 1 | 2008 | 11 | 0.070 |
Why?
|
| Atrial Natriuretic Factor | 1 | 1988 | 10 | 0.070 |
Why?
|
| Chromatography, High Pressure Liquid | 4 | 1989 | 83 | 0.070 |
Why?
|
| Cholecystectomy | 1 | 2008 | 21 | 0.070 |
Why?
|
| Synapses | 1 | 2009 | 87 | 0.070 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2008 | 1 | 0.070 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2008 | 30 | 0.070 |
Why?
|
| Herbal Medicine | 1 | 2008 | 4 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 2008 | 44 | 0.070 |
Why?
|
| Alleles | 3 | 2015 | 250 | 0.070 |
Why?
|
| Sphingosine | 1 | 2008 | 14 | 0.070 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2008 | 16 | 0.070 |
Why?
|
| Coproporphyrins | 2 | 1998 | 2 | 0.070 |
Why?
|
| Vitamin E | 2 | 2002 | 19 | 0.070 |
Why?
|
| Nervous System Diseases | 2 | 2001 | 46 | 0.070 |
Why?
|
| Hyaluronic Acid | 1 | 2008 | 51 | 0.070 |
Why?
|
| Lysophospholipids | 1 | 2008 | 26 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2012 | 101 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2008 | 114 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2007 | 77 | 0.070 |
Why?
|
| Oligonucleotides | 1 | 2007 | 26 | 0.070 |
Why?
|
| Heart Failure | 1 | 1994 | 728 | 0.070 |
Why?
|
| Hypertension | 1 | 2014 | 979 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2013 | 250 | 0.060 |
Why?
|
| Algorithms | 1 | 2010 | 536 | 0.060 |
Why?
|
| Hydrocarbons, Halogenated | 1 | 1987 | 1 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2007 | 48 | 0.060 |
Why?
|
| Splenectomy | 1 | 2007 | 22 | 0.060 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 155 | 0.060 |
Why?
|
| Self Administration | 1 | 2008 | 382 | 0.060 |
Why?
|
| Glucose-6-Phosphate Isomerase | 1 | 2006 | 1 | 0.060 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2006 | 8 | 0.060 |
Why?
|
| Altitude Sickness | 1 | 1986 | 2 | 0.060 |
Why?
|
| Endothelial Cells | 1 | 2008 | 193 | 0.060 |
Why?
|
| Phenelzine | 1 | 1986 | 1 | 0.060 |
Why?
|
| Genomics | 1 | 2007 | 89 | 0.060 |
Why?
|
| Drug Resistance, Viral | 1 | 2006 | 9 | 0.060 |
Why?
|
| Chlorobenzenes | 1 | 1986 | 1 | 0.060 |
Why?
|
| Hexachlorobenzene | 1 | 1986 | 1 | 0.060 |
Why?
|
| Lyases | 1 | 1986 | 1 | 0.060 |
Why?
|
| North America | 2 | 2013 | 31 | 0.060 |
Why?
|
| Hypercholesterolemia | 1 | 2006 | 73 | 0.060 |
Why?
|
| Cadmium | 2 | 1998 | 7 | 0.060 |
Why?
|
| Regression Analysis | 3 | 1997 | 273 | 0.060 |
Why?
|
| Immunoblotting | 4 | 2001 | 54 | 0.060 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2005 | 14 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 248 | 0.060 |
Why?
|
| Logistic Models | 3 | 2017 | 743 | 0.060 |
Why?
|
| Ethnic Groups | 3 | 2016 | 450 | 0.060 |
Why?
|
| Iran | 1 | 2004 | 5 | 0.060 |
Why?
|
| Weight Loss | 1 | 2008 | 410 | 0.050 |
Why?
|
| Cloning, Molecular | 2 | 1998 | 74 | 0.050 |
Why?
|
| Leucine Zippers | 1 | 2004 | 3 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2005 | 84 | 0.050 |
Why?
|
| Intestine, Small | 1 | 1985 | 43 | 0.050 |
Why?
|
| Acetamides | 1 | 1984 | 7 | 0.050 |
Why?
|
| Templates, Genetic | 1 | 2004 | 2 | 0.050 |
Why?
|
| Health Status | 1 | 2006 | 355 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2004 | 45 | 0.050 |
Why?
|
| beta-Galactosidase | 2 | 2001 | 14 | 0.050 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 2003 | 4 | 0.050 |
Why?
|
| Lipid Metabolism | 2 | 2015 | 108 | 0.050 |
Why?
|
| Liver Cirrhosis, Biliary | 3 | 1997 | 7 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2008 | 454 | 0.050 |
Why?
|
| Methylcholanthrene | 4 | 1988 | 7 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2010 | 773 | 0.050 |
Why?
|
| Survival Rate | 3 | 2010 | 893 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2017 | 1233 | 0.050 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2002 | 4 | 0.050 |
Why?
|
| DNA, Viral | 2 | 2009 | 55 | 0.050 |
Why?
|
| Hyperinsulinism | 1 | 2002 | 13 | 0.050 |
Why?
|
| Treatment Failure | 3 | 2009 | 165 | 0.050 |
Why?
|
| Leptin | 1 | 2002 | 61 | 0.050 |
Why?
|
| Iron-Binding Proteins | 1 | 2002 | 4 | 0.050 |
Why?
|
| Intestinal Absorption | 1 | 2002 | 21 | 0.050 |
Why?
|
| Oxidoreductases | 3 | 1991 | 25 | 0.040 |
Why?
|
| Mass Spectrometry | 2 | 2012 | 98 | 0.040 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2001 | 2 | 0.040 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2001 | 4 | 0.040 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2001 | 1 | 0.040 |
Why?
|
| Genistein | 1 | 2001 | 17 | 0.040 |
Why?
|
| Urea | 1 | 2001 | 38 | 0.040 |
Why?
|
| Subcellular Fractions | 2 | 2012 | 15 | 0.040 |
Why?
|
| Vasculitis | 1 | 2001 | 25 | 0.040 |
Why?
|
| Histocytochemistry | 2 | 2011 | 34 | 0.040 |
Why?
|
| Kidney Medulla | 1 | 2001 | 29 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2001 | 38 | 0.040 |
Why?
|
| Hemoglobins | 1 | 2001 | 45 | 0.040 |
Why?
|
| Actins | 1 | 2001 | 54 | 0.040 |
Why?
|
| Arthralgia | 1 | 2001 | 29 | 0.040 |
Why?
|
| Triglycerides | 1 | 2002 | 235 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2001 | 60 | 0.040 |
Why?
|
| Methoxamine | 1 | 2001 | 1 | 0.040 |
Why?
|
| Potassium Chloride | 1 | 2001 | 7 | 0.040 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2001 | 18 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2001 | 56 | 0.040 |
Why?
|
| Nitric Oxide Synthase | 1 | 2001 | 41 | 0.040 |
Why?
|
| Cell Fractionation | 2 | 2011 | 8 | 0.040 |
Why?
|
| Vasoconstriction | 1 | 2001 | 42 | 0.040 |
Why?
|
| Penetrance | 1 | 2021 | 4 | 0.040 |
Why?
|
| Microsomes | 2 | 1995 | 12 | 0.040 |
Why?
|
| Protein Conformation | 2 | 2011 | 110 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1991 | 18 | 0.040 |
Why?
|
| Lymphoma | 1 | 2001 | 37 | 0.040 |
Why?
|
| Species Specificity | 2 | 2013 | 98 | 0.040 |
Why?
|
| Pyruvate Dehydrogenase Complex | 2 | 1991 | 16 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2020 | 10 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 82 | 0.040 |
Why?
|
| Consensus Sequence | 1 | 2000 | 11 | 0.040 |
Why?
|
| Least-Squares Analysis | 1 | 2020 | 32 | 0.040 |
Why?
|
| Mammals | 1 | 2000 | 14 | 0.040 |
Why?
|
| Fat Necrosis | 1 | 2000 | 1 | 0.040 |
Why?
|
| Kynurenine | 2 | 1991 | 2 | 0.040 |
Why?
|
| Random Allocation | 2 | 2012 | 247 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2017 | 1479 | 0.040 |
Why?
|
| Tryptophan | 2 | 1991 | 7 | 0.040 |
Why?
|
| Epithelium | 2 | 1993 | 22 | 0.040 |
Why?
|
| Nausea | 1 | 2020 | 49 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 1999 | 17 | 0.040 |
Why?
|
| Benzodiazepines | 1 | 1999 | 10 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 1999 | 43 | 0.040 |
Why?
|
| Acetylcysteine | 1 | 1999 | 9 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1999 | 29 | 0.040 |
Why?
|
| Receptors, Interferon | 1 | 1999 | 2 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2011 | 204 | 0.040 |
Why?
|
| Animal Feed | 1 | 2019 | 23 | 0.040 |
Why?
|
| Fructose | 1 | 2019 | 11 | 0.040 |
Why?
|
| Genes, Recessive | 1 | 1999 | 8 | 0.040 |
Why?
|
| Dermatitis, Phototoxic | 1 | 2019 | 2 | 0.040 |
Why?
|
| Mesentery | 1 | 1999 | 6 | 0.040 |
Why?
|
| Photosensitivity Disorders | 1 | 2019 | 12 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2019 | 15 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 1999 | 69 | 0.040 |
Why?
|
| Somatotypes | 1 | 2019 | 1 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 53 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2019 | 80 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 79 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 114 | 0.040 |
Why?
|
| Radiometry | 1 | 2019 | 52 | 0.040 |
Why?
|
| Mephenytoin | 2 | 1989 | 2 | 0.040 |
Why?
|
| Spleen | 1 | 1999 | 84 | 0.040 |
Why?
|
| Cell Line, Transformed | 1 | 2018 | 18 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 1999 | 47 | 0.040 |
Why?
|
| European Continental Ancestry Group | 2 | 2016 | 1076 | 0.040 |
Why?
|
| Lipofuscin | 1 | 1998 | 3 | 0.040 |
Why?
|
| NADPH-Ferrihemoprotein Reductase | 2 | 1990 | 2 | 0.040 |
Why?
|
| Myositis | 1 | 1998 | 10 | 0.040 |
Why?
|
| Chemokine CCL3 | 1 | 2018 | 5 | 0.040 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2018 | 5 | 0.040 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2018 | 7 | 0.040 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2018 | 11 | 0.040 |
Why?
|
| Hepatitis, Animal | 1 | 1998 | 1 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 1998 | 9 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 96 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2018 | 34 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 1998 | 22 | 0.040 |
Why?
|
| Piperonyl Butoxide | 3 | 1987 | 3 | 0.040 |
Why?
|
| TATA Box | 1 | 1998 | 1 | 0.030 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 1998 | 15 | 0.030 |
Why?
|
| Flavonoids | 1 | 1998 | 20 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 1998 | 33 | 0.030 |
Why?
|
| Alcohols | 2 | 1989 | 3 | 0.030 |
Why?
|
| Introns | 1 | 1998 | 40 | 0.030 |
Why?
|
| Genetic Techniques | 1 | 1998 | 8 | 0.030 |
Why?
|
| Hot Temperature | 1 | 1998 | 81 | 0.030 |
Why?
|
| Exons | 1 | 1998 | 52 | 0.030 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2017 | 4 | 0.030 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2017 | 4 | 0.030 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1997 | 2 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 1997 | 7 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 1997 | 17 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1997 | 40 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2018 | 224 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2017 | 65 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 1997 | 29 | 0.030 |
Why?
|
| Coproporphyrinogen Oxidase | 1 | 1997 | 1 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 1 | 1997 | 61 | 0.030 |
Why?
|
| Virus Diseases | 1 | 1997 | 21 | 0.030 |
Why?
|
| Syndrome | 1 | 1997 | 66 | 0.030 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1996 | 1 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 106 | 0.030 |
Why?
|
| Early Diagnosis | 2 | 2008 | 56 | 0.030 |
Why?
|
| Bacterial Infections | 1 | 1997 | 45 | 0.030 |
Why?
|
| RNA | 1 | 1997 | 94 | 0.030 |
Why?
|
| Rats, Wistar | 2 | 2011 | 111 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 129 | 0.030 |
Why?
|
| HLA-DR Antigens | 1 | 1996 | 7 | 0.030 |
Why?
|
| Jaundice | 1 | 2016 | 5 | 0.030 |
Why?
|
| Cocarcinogenesis | 1 | 1996 | 2 | 0.030 |
Why?
|
| Body Weight | 2 | 2009 | 323 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2009 | 863 | 0.030 |
Why?
|
| Fluorometry | 1 | 2015 | 1 | 0.030 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2015 | 11 | 0.030 |
Why?
|
| Idarubicin | 1 | 2015 | 8 | 0.030 |
Why?
|
| Daunorubicin | 1 | 2015 | 27 | 0.030 |
Why?
|
| Polychlorinated Biphenyls | 2 | 1986 | 4 | 0.030 |
Why?
|
| Homozygote | 2 | 2010 | 52 | 0.030 |
Why?
|
| Drug Implants | 1 | 2015 | 10 | 0.030 |
Why?
|
| Cytochromes | 2 | 1986 | 2 | 0.030 |
Why?
|
| Epitopes | 2 | 2009 | 26 | 0.030 |
Why?
|
| Rheumatoid Factor | 1 | 1995 | 4 | 0.030 |
Why?
|
| Cryoglobulins | 1 | 1995 | 4 | 0.030 |
Why?
|
| Reference Values | 1 | 2015 | 238 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 1 | 1995 | 17 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2015 | 9 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 69 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2015 | 76 | 0.030 |
Why?
|
| Immunoelectrophoresis | 2 | 1985 | 2 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 1995 | 62 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 1995 | 64 | 0.030 |
Why?
|
| Amino Acids | 2 | 1992 | 52 | 0.030 |
Why?
|
| Adenomatous Polyps | 1 | 1994 | 8 | 0.030 |
Why?
|
| Colonic Polyps | 1 | 1994 | 17 | 0.030 |
Why?
|
| Diet | 2 | 1987 | 383 | 0.030 |
Why?
|
| Enzyme Repression | 1 | 1994 | 1 | 0.030 |
Why?
|
| Spectrophotometry | 2 | 1984 | 22 | 0.030 |
Why?
|
| Peroxidase | 1 | 1994 | 27 | 0.030 |
Why?
|
| Colonoscopy | 1 | 1994 | 45 | 0.030 |
Why?
|
| Myosins | 1 | 2014 | 12 | 0.030 |
Why?
|
| Macrophages | 1 | 1996 | 207 | 0.030 |
Why?
|
| Cytoplasm | 1 | 2014 | 29 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 168 | 0.030 |
Why?
|
| Rectal Prolapse | 1 | 1994 | 2 | 0.030 |
Why?
|
| Rectum | 1 | 1994 | 18 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 1998 | 520 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 443 | 0.030 |
Why?
|
| Cardiac Output | 2 | 1991 | 33 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 1995 | 152 | 0.030 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2010 | 42 | 0.030 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2013 | 34 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 1994 | 48 | 0.030 |
Why?
|
| Anal Canal | 1 | 1994 | 34 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2013 | 56 | 0.030 |
Why?
|
| Tin | 1 | 1993 | 2 | 0.030 |
Why?
|
| Benzamides | 1 | 2013 | 60 | 0.030 |
Why?
|
| Piperazines | 1 | 2013 | 60 | 0.030 |
Why?
|
| Copper | 1 | 1993 | 11 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2015 | 666 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 565 | 0.020 |
Why?
|
| Zinc | 1 | 1993 | 29 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2013 | 77 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2013 | 7 | 0.020 |
Why?
|
| STAT2 Transcription Factor | 1 | 2013 | 1 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2013 | 13 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 1993 | 132 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 288 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2013 | 43 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2013 | 28 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2013 | 74 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2013 | 124 | 0.020 |
Why?
|
| Liver Glycogen | 1 | 1992 | 3 | 0.020 |
Why?
|
| Bone Density | 2 | 1991 | 169 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 181 | 0.020 |
Why?
|
| Paintings | 1 | 1992 | 2 | 0.020 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 1992 | 5 | 0.020 |
Why?
|
| Netherlands | 1 | 1992 | 25 | 0.020 |
Why?
|
| History, 19th Century | 1 | 1992 | 14 | 0.020 |
Why?
|
| Alcoholic Beverages | 1 | 1992 | 5 | 0.020 |
Why?
|
| Space Flight | 1 | 1992 | 23 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2012 | 43 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2012 | 19 | 0.020 |
Why?
|
| Genome, Human | 1 | 2012 | 130 | 0.020 |
Why?
|
| Fatty Liver, Alcoholic | 1 | 2011 | 1 | 0.020 |
Why?
|
| Candida | 1 | 2011 | 7 | 0.020 |
Why?
|
| Virus Cultivation | 1 | 2011 | 3 | 0.020 |
Why?
|
| Tetanus Toxin | 1 | 2011 | 5 | 0.020 |
Why?
|
| Recombination, Genetic | 1 | 2011 | 23 | 0.020 |
Why?
|
| NADH Dehydrogenase | 1 | 1991 | 4 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2011 | 17 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 1991 | 15 | 0.020 |
Why?
|
| Liver Circulation | 1 | 1991 | 7 | 0.020 |
Why?
|
| Galactose | 1 | 1991 | 3 | 0.020 |
Why?
|
| Osteocalcin | 1 | 1991 | 9 | 0.020 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 1991 | 19 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 132 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 43 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2011 | 136 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2000 | 1437 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 146 | 0.020 |
Why?
|
| Biotransformation | 1 | 1991 | 4 | 0.020 |
Why?
|
| Aflatoxin B1 | 1 | 1991 | 3 | 0.020 |
Why?
|
| Liver Regeneration | 1 | 2011 | 23 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 90 | 0.020 |
Why?
|
| Apoproteins | 1 | 2011 | 3 | 0.020 |
Why?
|
| Rabbits | 1 | 1991 | 219 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 101 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2011 | 25 | 0.020 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.020 |
Why?
|
| Gene Library | 1 | 1991 | 7 | 0.020 |
Why?
|
| DNA Probes | 1 | 1991 | 18 | 0.020 |
Why?
|
| Ketone Oxidoreductases | 1 | 1991 | 2 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 183 | 0.020 |
Why?
|
| Lysosomes | 1 | 1991 | 10 | 0.020 |
Why?
|
| Free Radicals | 1 | 1991 | 10 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 1991 | 19 | 0.020 |
Why?
|
| Bone and Bones | 1 | 1991 | 91 | 0.020 |
Why?
|
| Ascorbic Acid | 1 | 1991 | 21 | 0.020 |
Why?
|
| Potassium | 1 | 1991 | 40 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 1991 | 76 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 40 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2011 | 173 | 0.020 |
Why?
|
| Safety | 1 | 2010 | 65 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 543 | 0.020 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1990 | 4 | 0.020 |
Why?
|
| Chromatography | 1 | 1990 | 4 | 0.020 |
Why?
|
| Chromatography, Gel | 1 | 1990 | 16 | 0.020 |
Why?
|
| Durapatite | 1 | 1990 | 9 | 0.020 |
Why?
|
| Cations | 1 | 1990 | 9 | 0.020 |
Why?
|
| Hydroxyapatites | 1 | 1990 | 3 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1990 | 27 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1990 | 55 | 0.020 |
Why?
|
| Creatinine | 1 | 2010 | 191 | 0.020 |
Why?
|
| Cause of Death | 1 | 2011 | 236 | 0.020 |
Why?
|
| Cattle | 1 | 1990 | 116 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 1990 | 89 | 0.020 |
Why?
|
| Prothrombin | 1 | 2009 | 1 | 0.020 |
Why?
|
| Drinking Behavior | 1 | 2009 | 11 | 0.020 |
Why?
|
| Forecasting | 1 | 1990 | 144 | 0.020 |
Why?
|
| Peritonitis | 1 | 2009 | 13 | 0.020 |
Why?
|
| Polycyclic Compounds | 1 | 1989 | 1 | 0.020 |
Why?
|
| Isomerism | 1 | 1989 | 6 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2010 | 211 | 0.020 |
Why?
|
| Carrier State | 1 | 2009 | 22 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2009 | 58 | 0.020 |
Why?
|
| Metals | 1 | 1989 | 18 | 0.020 |
Why?
|
| African Americans | 1 | 2016 | 1335 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2009 | 23 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2010 | 187 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 762 | 0.020 |
Why?
|
| Mitochondria, Heart | 1 | 2009 | 17 | 0.020 |
Why?
|
| Succinates | 1 | 2009 | 6 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1989 | 17 | 0.020 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2009 | 5 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1A2 | 2 | 1986 | 3 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 141 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 155 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 80 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 194 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2009 | 68 | 0.020 |
Why?
|
| Methemoglobin | 1 | 1988 | 1 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 388 | 0.020 |
Why?
|
| Microchemistry | 1 | 1988 | 5 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1988 | 69 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2008 | 31 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1988 | 25 | 0.020 |
Why?
|
| Procollagen | 1 | 2008 | 7 | 0.020 |
Why?
|
| Specimen Handling | 1 | 1988 | 30 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 1988 | 4 | 0.020 |
Why?
|
| Phenylhydrazines | 1 | 2008 | 1 | 0.020 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2008 | 5 | 0.020 |
Why?
|
| Aldehyde-Lyases | 1 | 2008 | 5 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2008 | 12 | 0.020 |
Why?
|
| Computers | 1 | 2008 | 22 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 39 | 0.020 |
Why?
|
| Haplotypes | 1 | 2008 | 213 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2008 | 34 | 0.020 |
Why?
|
| Iron Carbonyl Compounds | 1 | 1987 | 1 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2008 | 96 | 0.020 |
Why?
|
| Anemia | 1 | 2008 | 50 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2008 | 68 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 2008 | 68 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2008 | 108 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2008 | 58 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 1989 | 312 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2008 | 194 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 393 | 0.020 |
Why?
|
| Drainage | 1 | 1987 | 65 | 0.020 |
Why?
|
| Cytoplasmic Granules | 2 | 1998 | 7 | 0.020 |
Why?
|
| Research Design | 1 | 2009 | 314 | 0.020 |
Why?
|
| Polybrominated Biphenyls | 1 | 1986 | 1 | 0.020 |
Why?
|
| Aminopyrine N-Demethylase | 1 | 1986 | 1 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2006 | 22 | 0.020 |
Why?
|
| Glucose-6-Phosphatase | 1 | 1986 | 4 | 0.020 |
Why?
|
| Cytochrome b Group | 1 | 1986 | 5 | 0.020 |
Why?
|
| Cytochromes b5 | 1 | 1986 | 2 | 0.020 |
Why?
|
| Lipid Peroxides | 1 | 1986 | 7 | 0.020 |
Why?
|
| Tetrapyrroles | 1 | 1986 | 1 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1987 | 164 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2006 | 12 | 0.020 |
Why?
|
| Extracellular Space | 1 | 1986 | 28 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1986 | 43 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2006 | 65 | 0.010 |
Why?
|
| Immunoassay | 1 | 1985 | 16 | 0.010 |
Why?
|
| Bone Marrow | 1 | 2005 | 68 | 0.010 |
Why?
|
| Taq Polymerase | 1 | 2005 | 1 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 1985 | 8 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 1985 | 138 | 0.010 |
Why?
|
| Complementarity Determining Regions | 1 | 2005 | 2 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2008 | 414 | 0.010 |
Why?
|
| ROC Curve | 1 | 2005 | 169 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2005 | 25 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1989 | 907 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2005 | 31 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2005 | 59 | 0.010 |
Why?
|
| Apoenzymes | 1 | 1984 | 3 | 0.010 |
Why?
|
| Methionine Sulfoximine | 1 | 1984 | 1 | 0.010 |
Why?
|
| Phenolsulfonphthalein | 1 | 1984 | 1 | 0.010 |
Why?
|
| Buthionine Sulfoximine | 1 | 1984 | 2 | 0.010 |
Why?
|
| Glucuronates | 1 | 1984 | 4 | 0.010 |
Why?
|
| Graft Survival | 1 | 2005 | 293 | 0.010 |
Why?
|
| Dithionite | 1 | 1984 | 4 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2005 | 245 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2001 | 11 | 0.010 |
Why?
|
| Fluoresceins | 1 | 2001 | 9 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2001 | 32 | 0.010 |
Why?
|
| Light | 1 | 2000 | 35 | 0.010 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 1999 | 2 | 0.010 |
Why?
|
| HIV Infections | 1 | 2005 | 450 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1998 | 3 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1998 | 5 | 0.010 |
Why?
|
| Genome, Viral | 1 | 1998 | 12 | 0.010 |
Why?
|
| Sarcolemma | 1 | 1998 | 4 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 1998 | 19 | 0.010 |
Why?
|
| Isoproterenol | 1 | 1998 | 17 | 0.010 |
Why?
|
| Myoglobin | 1 | 1998 | 11 | 0.010 |
Why?
|
| Fluorescence | 1 | 1998 | 22 | 0.010 |
Why?
|
| Chemotactic Factors | 1 | 1998 | 3 | 0.010 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1998 | 22 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 1998 | 27 | 0.010 |
Why?
|
| Neutrophils | 1 | 1998 | 120 | 0.010 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1997 | 20 | 0.010 |
Why?
|
| Myocardium | 1 | 1998 | 184 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1998 | 232 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1997 | 757 | 0.010 |
Why?
|
| Cell Compartmentation | 1 | 1994 | 4 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 1998 | 465 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1994 | 151 | 0.010 |
Why?
|
| Osteoblasts | 1 | 1991 | 43 | 0.010 |
Why?
|
| 3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 1991 | 1 | 0.010 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1991 | 9 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1991 | 24 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1990 | 46 | 0.010 |
Why?
|
| Vitamin D | 1 | 1991 | 186 | 0.000 |
Why?
|
| Vascular Resistance | 1 | 1987 | 32 | 0.000 |
Why?
|
| Ellipticines | 1 | 1986 | 1 | 0.000 |
Why?
|
| 2-Acetylaminofluorene | 1 | 1986 | 7 | 0.000 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 1984 | 12 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1987 | 861 | 0.000 |
Why?
|